DEBORAH DE SA PEREIRA BELFORT
Índice h a partir de 2011
2
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina - Médico
6 resultados
Resultados de Busca
Agora exibindo 1 - 6 de 6
- Is There a Role for Telemonitoring in Heart Failure?(2022) AVILA, Monica Samuel; BELFORT, Deborah de Sa Pereira
- Aortic and Renal Artery Thrombosis as the First Clinical Manifestation of COVID-19 in a Heart Transplant Recipient(2021) BELFORT, Deborah de Sa Pereira; MARCONDES-BRAGA, Fabiana G.; MANGINI, Sandrigo; CAFEZEIRO, Caio Reboucas Fonseca; FURLAN, Diogenes Amauri Goncalves; BACAL, Fernando
- Progress in Heart Transplantation in Brazil: is it Time to Build a National Database?(2021) AVILA, Monica Samuel; BELFORT, Deborah de Sa Pereira
- Is There a Role for Lung Ultrasonography in the Prognosis of Heart Failure Patients?(2021) AVILA, Monica Samuel; BELFORT, Deborah De Sa Pereira
- COVID-19 complicating perioperative management of LVAD implantation: A case report and systematic review(2021) BELFORT, Deborah de Sa Pereira; BISELLI, Bruno; AVILA, Monica Samuel; LIRA, Maria Tereza Sampaio de Sousa; GALAS, Filomena Regina Barbosa Gomes; STEFFEN, Samuel Padovani; GAIOTTO, Fabio Antonio; JATENE, Fabio Biscegli; BOCCHI, Edimar Alcides; FERREIRA, Silvia Moreira AyubThe coronavirus 2019 disease (COVID-19) affected 125 million people worldwide and caused 2.7 million deaths. Some comorbidities are associated with worse prognosis and left ventricular assist device (LVAD) recipients are probably part of this high-risk population. We report a 31-year-old male patient who developed COVID-19 during LVAD implantation. His postoperative period was complicated by severe pneumonia and mechanical ventilation (MV) leading to right ventricular failure (RVF) and inotrope necessity. He experienced multiple complications, but eventually recovered. We present a systematic review of LVAD recipients and COVID-19. Among 14 patients, the mean age was 62.7 years, 78.5% were male. A total of 5 patients (35.7%) required MV and 3 patients (21.4%) died. A total of 2 patients (14.2%) had thromboembolic events. This case and systematic review suggest LVAD recipients are at particular risk of unfavorable outcomes and they may be more susceptible to RVF in the setting of COVID-19, particularly during perioperative period.
- Characteristics and Outcomes of Heart Transplant Recipients With Coronavirus-19 Disease in a High-volume Transplant Center(2022) MARCONDES-BRAGA, Fabiana G.; MURAD, Ciro M.; BELFORT, Deborah S. P.; DANTAS, Rafael C. T.; LIRA, Maria Tereza S. S.; ARAGAO, Carlos A. S.; SICILIANO, Rinaldo F.; MANGINI, Sandrigo; SEGURO, Luis Fernando B. C.; CAMPOS, Iascara W.; AVILA, Monica S.; BELLO, Mariana V. O.; SANTOS, Fernanda B. A. dos; V, Tania M. Strabelli; GAIOTTO, Fabio A.; BACAL, FernandoBackground. Heart transplant (HT) recipients may be at higher risk of acquiring SARS-CoV-2 infection and developing critical illness. The aim of this study is to describe characteristics and outcomes of HT recipients infected by SARS-COV-2, from a high-volume transplant center. Methods. We have described data of all adult HT recipients with confirmed coronavirus disease 2019 by RT-PCR in nasopharyngeal samples from April 5, 2020, to January 5, 2021. Outcomes and follow-up were recorded until February 5, 2021. Results. Forty patients were included. Twenty-four patients (60%) were men; the median age was 53 (40-60) y old; median HT time was 34 mo; and median follow-up time 162 d. The majority needed hospitalization (83%). Immunosuppressive therapy was reduced/withdrawn in the majority of patients, except from steroids, which were maintained. Seventeen patients (42.5%) were classified as having severe disease according to the ordinal scale developed by the World Health Organization Committee. They tended to have lower absolute lymphocyte count (P < 0.001) during follow-up when compared with patients with mild disease. Thirty-day mortality was 12.5%. However, a longer follow-up revealed increased later mortality (27.5%), with median time to death around 35 d. Bacterial nosocomial infections were a leading cause of death. Cardiac allograft rejection (10%) and ventricular dysfunction (12.5%) were also not negligible. Conclusions. Major findings of this study corroborate other cohorts' results, but it also reports significant rate of later events, suggesting that a strict midterm surveillance is advisable to HT recipients with coronavirus disease 2019.